Weekly Research Analysts’ Ratings Updates for Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (NASDAQ: REGN) recently received a number of ratings updates from brokerages and research firms:

• 11/2/2026 – Regeneron Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Leerink Partners from $835.00 to $997.00. They now have a “market perform” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Sanford C. Bernstein from $756.00 to $812.00. They now have a “market perform” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Morgan Stanley from $779.00 to $855.00. They now have an “equal weight” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Truist Financial from $780.00 to $982.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Royal Bank Of Canada from $810.00 to $913.00. They now have a “sector perform” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Guggenheim from $1,030.00 to $1,100.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Wells Fargo & Company from $750.00 to $925.00. They now have an “equal weight” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Bank of America from $908.00 to $1,030.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Robert W. Baird from $761.00 to $875.00. They now have a “neutral” rating on the stock.
• 11/2/2026 – Regeneron Pharmaceuticals had its price target raised by Cantor Fitzgerald from $795.00 to $980.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Regeneron Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $950.00 to $1,050.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Regeneron Pharmaceuticals had its price target raised by Citigroup from $740.00 to $825.00. They now have a “neutral” rating on the stock.
• 10/28/2026 – Regeneron Pharmaceuticals had its price target raised by Canaccord Genuity Group from $875.00 to $922.00. They now have a “buy” rating on the stock.
• 10/21/2026 – Regeneron Pharmaceuticals had its price target raised by TD Cowen from $960.00 to $980.00. They now have a “buy” rating on the stock.
• 10/19/2026 – Regeneron Pharmaceuticals had its price target raised by Piper Sandler from $854.00 to $865.00. They now have an “overweight” rating on the stock.
• 10/15/2026 – Regeneron Pharmaceuticals was upgraded by UBS Group from “neutral” to “buy”. They now have a $978.00 price target on the stock, up from $660.00.
• 10/8/2026 – Regeneron Pharmaceuticals had its price target raised by Royal Bank Of Canada from $737.00 to $810.00. They now have a “sector perform” rating on the stock.
• 10/7/2026 – Regeneron Pharmaceuticals had its price target raised by Truist Financial from $772.00 to $780.00. They now have a “buy” rating on the stock.
• 10/7/2026 – Regeneron Pharmaceuticals had its price target raised by Morgan Stanley from $758.00 to $779.00. They now have an “equal weight” rating on the stock.
• 10/6/2026 – Regeneron Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $900.00 to $950.00. They now have an “overweight” rating on the stock.
• 10/1/2026 – Regeneron Pharmaceuticals had its price target raised by Jefferies Financial Group from $870.00 to $930.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Regeneron Pharmaceuticals was upgraded by Argus from “hold” to “buy”. They now have a $850.00 price target on the stock.
• 9/29/2026 – Regeneron Pharmaceuticals had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $737.00 price target on the stock.
• 9/28/2026 – Regeneron Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
• 9/21/2026 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 9/20/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 9/12/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 9/10/2026 – Regeneron Pharmaceuticals had its price target raised by HSBC from $800.00 to $920.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Regeneron Pharmaceuticals had its price target raised by BMO Capital Markets from $800.00 to $920.00. They now have an “outperform” rating on the stock.

Regeneron Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ REGN traded up $2.07 during trading on Friday, hitting $904.97. 119,170 shares of the company traded hands, compared to its average volume of 830,122. The company has a 50-day moving average price of $802.45 and a 200-day moving average price of $741.95. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73. The firm has a market capitalization of $93.17 billion, a P/E ratio of 19.98, a P/E/G ratio of 1.38 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm’s quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.83 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 51.86 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Zoghbi sold 7,439 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,652,693.38. The trade was a 81.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Andrew Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 28,228 shares of company stock valued at $25,985,950 over the last three months. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.